From January 1, 2022, the national medical insurance drug catalogue in 2021 will be officially implemented.
According to chinanews.com, on December 28, Beijing took the lead in adjusting the medical insurance drug catalogue, adjusting the reimbursement scope and category of some drugs, and improving the drug reimbursement policies for outpatient special diseases, etc. Consistent with the previous adjustment results of the national medical insurance drug catalogue in 2021 announced on December 3, all 74 drugs added by the country were included in the Beijing medical insurance drug catalogue. The new policy will also be officially implemented from January 1, 2022, and is applicable to urban employees, urban and rural residents and other insured persons.
A total of 117 varieties of medical insurance adjustment this year were included in the negotiation scope, and 94 were finally negotiated, including the original 27 varieties in the directory and 67 new varieties. The overall success rate of the negotiation was as high as 80.34%.
Not only the success rate of the negotiation is high, but also the bargaining power of the national medical insurance bureau is not small. In 2021, the average price reduction of Medicare listed drugs was 61.71%, which was significantly greater this year than the average price reduction of 50.64% in 2020. This is the result of the joint efforts of all sectors of society. The total number of drugs in the catalogue is up to 2860, which will be implemented on January 1, 2022.
According to the news previously released by the National Medical Insurance Bureau, compared with previous years, the number of drugs transferred into the medical insurance directory in 2020 is the largest and the most widely beneficial fields, including the tumor immunotherapy drug PD-1 monoclonal antibody.
At present, there are 8 immune checkpoint inhibitors on the market in China. Four of them are domestic PD-1. The most intuitive impact on patients is to directly pull the price of PD-1 from 300000 yuan / year, which is "not affordable", to about 100000 yuan / year.
In 2019, xindilimab injection, a domestic innovative PD-1 inhibitor with international quality, was first included in the medical insurance. It is also the lowest price PD-1 at present. The price of medical insurance after price reduction is only 2843 yuan / piece.
In 2020, the national medical insurance catalogue will include all the other three domestic PD-1 mAbs. With the implementation of the new medical insurance catalogue on March 1, 2021, the price reduction of the three PD-1 anticancer drugs after "soul bargaining" is more than 70%.
The most shocking and surprising thing about entering the medical insurance last year was that Erica (carrelizumab for injection) 200mg / piece of Hengrui medicine reduced the price from 19800 to 2928 yuan / piece. If charitable gifts are not counted, the decrease will reach 85%!
Carrelizumab is a PD-1 monoclonal antibody developed by Hengrui medicine in China, and has independent intellectual property rights. Among them, four approved indications entered the medical insurance, including recurrent / refractory Hodgkin's lymphoma (line 3), hepatocellular carcinoma (line 2), non-squamous non-small cell lung cancer (line 1 combination) and esophageal squamous cell carcinoma (line 2). The above are all high-risk cancer species in China, which can be said to have an advantage in indications.
The annual treatment cost of the biweekly treatment scheme for lymphoma is about 70000 yuan, which is slightly lower than that of Baiji Shenzhou.
On January 1, 2022, the state negotiated price will be implemented.
According to the published price of domestic PD-1 medical insurance:
The prices of the four PD-1 models are:
● cindilimab: 1080 yuan (10ml / 100mg / bottle); Annual treatment cost: 37400 / year
● treprizumab: 1912.96 yuan (6ml / 240mg / bottle); Annual treatment cost: 33200 / year
● tirelizumab: 1450 yuan (10ml / 100mg / bottle); Annual treatment cost: 50300 / year
● carrelizumab: 2928 yuan (200mg / bottle); Annual treatment cost: 50700 / year
Price of non Medicare PD - (L1) immune drugs:
● pabolizumab: 17918 yuan (4ml / 0.1g / dose); Annual treatment cost: 140000 / 2 years
● nabuliumab: 9260 yuan / 100mg; 4591 yuan / 40mg; Annual treatment cost: 110000 yuan / year
● duvalizumab: 18088 yuan / 500mg; 6066 yuan / 120mg
● atilizumab: 32800 yuan / 1200mg; Annual treatment cost: 131200 / year
This time, the price of cindilimab was reduced to 1080 yuan (10ml / 100mg / bottle), and the previous medical insurance price was 2843 yuan (10ml: 100mg / bottle), a decrease of 62%! It is awesome!
The price of treprizumab after entering medical insurance in 2021 is 906.08 yuan (specification: 80mg); The quotation for 100mg (2.5ml) is 1074.87 yuan / piece, and that for 240mg (6ml) is 2100.97 yuan / piece. The price of 1912.96 yuan (6ml / 240mg / bottle) is slightly lower than before.
The previous price of tirelizumab was 10688 yuan (100mg), and the price after medical insurance in 2021 became 2180 yuan. The price is 1450 yuan (10ml / 100mg / bottle), and the price reduction is 33%.
The price of carrelizumab remains at 2928 yuan (200mg / bottle), the same as last year.
Source: global network of oncologists
http://www.globecancer.com/azzx/show.php?itemid=14704
